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ABSTRACT
ObjectiveTodevelop,validate,andevaluateanewQRISK
model to estimate lifetime risk of cardiovascular disease.
Design Prospective cohort study with routinely collected
data from general practice. Cox proportional hazards
models in the derivation cohort to derive risk equations
accounting for competing risks. Measures of calibration
and discrimination in the validation cohort.
Setting 563 general practices in England and Wales
contributing to the QResearch database.
Subjects Patients aged 30–84 years who were free of
cardiovascular disease and not taking statins between
1 January 1994 and 30 April 2010: 2343759 in the
derivation dataset, and 1267159 in the validation
dataset.
Main outcomes measures Individualised estimate of
lifetime risk of cardiovascular disease accounting for
smoking status, ethnic group, systolic blood pressure,
ratio of total cholesterol:high density lipoprotein
cholesterol, body mass index, family history of coronary
heart disease in first degree relative aged <60 years,
Townsend deprivation score, treated hypertension,
rheumatoid arthritis, chronic renal disease, type 2
diabetes, and atrial fibrillation. Age-sex centile values for
lifetime cardiovascular risk compared with 10 year risk
estimated using QRISK2 (2010).
ResultsAcrossallthe1267159patientsinthevalidation
dataset, the 50th, 75th, 90th, and 95th centile values for
lifetimeriskwere 31%, 39%,50%, and57% respectively.
Of the 10% of patients in the validation cohort classified
at highest risk with either the lifetime risk model or the
10 year risk model, only 18385(14.5%) were at high risk
onbothmeasures.Patientsidentifiedashighriskwiththe
lifetime risk approach were more likely to be younger,
male, from ethnic minority groups, and have a positive
family history of premature coronary heart disease than
those identified with the 10 year QRISK2 score. The
lifetime risk calculator is available at www.qrisk.org/
lifetime/.
Conclusions Compared with using a 10 year QRISK2
score,alifetimeriskscorewilltendtoidentifypatientsfor
intervention at a younger age. Although lifestyle
interventions at an earlier age could be advantageous,
there would be small gains under the age of 65, and
medical interventions carry risks as soon as they are
initiated. Research is needed to examine closely the cost
effectiveness and acceptability of such an approach.
INTRODUCTION
Cardiovascular disease is the leading cause of prema-
ture death and a major cause of disability in the UK.
1
National policies now support targeting of inter-
ventions to reduce risk of cardiovascular disease
among high risk patients.
2-5 Validated risk prediction
algorithms, such as QRISK2,
6-8 are used in such pro-
grammes to identify patients for intervention when
they are at high risk—defined by a 10 year cardio-
vascular disease threshold of ≥20%.
3
Applying this 20% risk threshold for intervention
may not identify younger patients who, because of
their age, have a low absolute 10 year risk but who
have a high relative risk compared with their peers.
Thisisbecauseagehassuchadominanteffectincalcu-
lating absolute cardiovascular risk. Some argue that
younger patients with an adverse risk profile may
have more to gain during their lifetime if interventions
are started at a younger age rather than waiting until
they cross the 20% threshold.
9-12 Lifetime risks which
measure the cumulative risk of developing a disease
during the remainder of an individual’s life
13 would
reflect this relatively high risk and, given that lifetime
risk estimates provide assessment over the full life
course, they may provide a more appropriate assess-
ment of future risks than estimates limited to
10 years, particularly at younger ages.
911
There are currently no published algorithms that
estimatelifetimeriskofcardiovasculardiseasederived
from contemporaneous UK data, and none which
incorporates social deprivation or ethnicity.
12 We
therefore developed, validated, and evaluated a new
QRISK model to estimate individualised lifetime risk
ofcardiovasculardiseaseusingroutinelycollecteddata
from UK general practice.
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Study design and data source
We conducted a prospective cohort study in a large
population of primary care patients from an open
cohort study using the QResearch database (version
29).We includedall participating practicesin England
and Wales who had been using their EMIS (Egton
Medical Information System) computer system for at
leastayear.Werandomlyallocatedtwothirdsofprac-
tices to a derivation dataset and retained a third for a
validation dataset. We identified an open cohort of
patients aged 30–84 years drawn from patients regis-
tered with practices between 1 January 1994 and 30
April 2010. We excluded patients who did not have a
postcoderelatedTownsenddeprivationscore(5.2%of
patients),thosewhohadbeenprescribedstatinsbefore
the study start date (3.0% of patients), and those with
pre-existingcardiovasculardisease(3.6%).Entrytothe
cohort was the latest date of the study start date (1 Jan-
uary1994),thedatethepatientbecame30yearsold,or
12monthsafterthepatientregisteredwiththepractice.
Clinical outcomes
We identified incident cases of cardiovascular disease
based on the first recordeddiagnosis of cardiovascular
diseaserecordedonthegeneralpracticecomputersys-
tem or their linked death certificate during the study
period.
6-8 The term cardiovascular includes coronary
heart disease (angina and myocardial infarction),
stroke, or transient ischaemic attacks, but not periph-
eralvasculardisease.Wedefinedothercausesofdeath
as deaths in patients without recorded evidence of
cardiovascular disease as defined above.
Predictor and exposure variables
We used the same predictor variables as QRISK2,
6
with the exception of smoking status (which we cate-
gorised as a five level variable) and age (which we
included as the underlying time function rather than
as a predictor variable). The following variables were
included in the final models for men and women sepa-
rately:
 Smoking status (heavy smoker (≥20 cigarettes/
day), moderate smoker (10–19/day), light
smoker (<10/day), former smoker, non-smoker)
 Self-assigned ethnicity (white (or not recorded),
Indian, Pakistani, Bangladeshi, other Asian,
black African, black Caribbean, Chinese, other
(including mixed))
 Systolic blood pressure (continuous)
 Ratio of total serum cholesterol to high density
lipoprotein (HDL) cholesterol (continuous)
 Body mass index (weight (kg)/(height (m)
2)
(continuous)
 Family history of coronary heart disease in first
degree relative aged <60 years (yes/no)
 Townsend deprivation score
8 (output area level
2001 census data evaluated as a continuous
variable)
 Treated hypertension (diagnosis of hypertension
and at least one current prescription of at least
one antihypertensive agent)
 Rheumatoid arthritis (yes/no)
 Atrial fibrillation (yes/no)
 Type 2 diabetes (yes/no)
 Chronic renal disease (yes/no), based on
presence of diagnostic codes as in QRISK2
14
rather than defined by glomerular filtration rates.
Statistical modelling
Weusedmultipleimputationtoreplacemissingvalues
forsystolicbloodpressure,totalcholesterol:HDLcho-
lesterol ratio, smoking status, and body mass index.
We used the ICE procedure in STATA for imputation
and included all the predictor variables listed above
plus the survival outcome variables for cardiovascular
disease and non-cardiovascular death. We carried out
conditional imputation for smoking status. This
allowed us to impute a smoking quantity for current
smokers when the quantity smoked was not recorded.
Our final model was based on five multiply imputed
datasets using Rubin’s rules to combine effect esti-
mates and estimate standard errors to allow for the
uncertainty due to missing data.
1516 We used the
same fractional polynomial terms for body mass
index as in QRISK2 (2010).
Wedevelopedthemodeltoestimatethelifetimerisk
of cardiovascular disease, with death (non-cardio-
vascular) accounted for as a competing risk. Lifetime
risk conveys the cumulative risk of developing a dis-
ease during the remainder of an individual’s life.
13
Competing risk analyses are recommended among
elderly populations where a significant proportion of
patients may not experience the outcome of interest
(such as cardiovascular disease) because they have
already experienced a “competing event” such as
death.
17 Failure to account for death as a competing
risk will tend to overestimate cardiovascular risk
among the elderly. We used cause-specific hazard
modelstoaccountforcompetingrisks,whichinvolved
fitting two separate Cox models—one for cardio-
vascular disease and one for deaths from other causes
—including the same predictor variables in both mod-
els. Patients who didn’t die or have cardiovascular dis-
easewerecensoredattheearliestdateofderegistration
with the practice, last upload of computerised data, or
the study end date (30 April 2010).
In previous QRISK models, we used time since
cohort entry as the underlying time function in the
Cox regression and incorporated age and its inter-
actions as predictor variables in the final model. In
this analysis, we used age as the underlying time func-
tion in the Cox regression by setting the origin as the
patient’s date of birth, as done elsewhere,
18 and defin-
ing a delayed entry date as the study entry date. This
allows estimation of cause-specific hazard rates across
the age range from the youngest age at study entry to
the latest age at study exit.
We used a published formula
19 to derive the cumu-
lative incidence function for cardiovascular disease,
RESEARCH
page 2 of 10 BMJ | ONLINE FIRST | bmj.comaccounting for competing events, using estimates
obtainedfrom the two Cox models.Thisformula mul-
tiplies the hazard contribution for cardiovascular dis-
ease at a given age by the probability of being both
alive and free from cardiovascular disease at that age,
and then sums these values across the age range of
interest.Itcan beusedtocalculatethecumulativeinci-
dence function for a patient based on his or her age at
baseline and up to any age less than the latest age at
study exit, and can also incorporate the patient’s cov-
ariate values to estimate individual cumulative inci-
dence values. We used this method to estimate the
lifetime risk for each patient including events up to
the age of 95 years. We used the cut point of 95 years
in our definition for lifetime risk as this is consistent
with the value used in other studies of lifetime risk.
11
Alsofewpatientslivebeyondthisage.Thiscalculation
incorporates estimates of the probability each patient
will be alive and free from cardiovascular disease for
ages up to 95, accounting for his or her individual risk
factors rather than applying population values of life
expectancy as in some other studies.
18 We used the
same method to evaluate the 10 year risk for each
patient.
In order to validate the performance of the lifetime
model at 10 years, we applied the algorithms to our
validation cohort and calculated measures of discrimi-
nation (R
2 statistic for survival data
20 and area under
the receiver operating characteristic curve (ROC sta-
tistic)).In ordertodetermine the calibrationofthe life-
timeriskmodel,wecomparedobservedwithpredicted
lifetime risks by 10th of predicted risk, taking account
of competing risks in the calculation of observed risks.
We examined the distribution of lifetime risk esti-
mates and calculated age-sex centile values using
methods developed by Royston
21 and compared the
distribution with the 10 year risk estimates derived
from QRISK2 (2010). We also compared characteris-
tics of the top 10% of patients with the highest lifetime
risk with those for the top 10% of patients with highest
10 year risk based on QRISK2 (2010).
We used all the available data in the derivation
cohort to develop the model and all the available data
from the validation cohort to test its performance. We
used STATA (version 11) for all analyses.
RESULTS
Characteristics of the study population
Overall, 563 QResearch practices in England and
Wales met our inclusion criteria: 374 were randomly
assigned to the derivation dataset, and the remainder
becamethevalidationdataset.Weidentified2509517
patients aged 30–84 years at study entry in the deriva-
tion cohort with complete Townsend scores, of whom
78619weretakingstatinsandafurther87139hadpre-
existing cardiovascular disease, leaving 2343759
patients for analysis.
Weidentified1353435patientsaged30–84atstudy
entryinthevalidationcohortwithcompleteTownsend
scores, of whom 38047 were taking statins and a
further48229hadpre-existingcardiovasculardisease,
leaving 1267159 patients for analysis. Table 1 com-
pares the baseline characteristics of the patients in the
derivation and validation cohorts, which were similar,
and similar to those reported in previous studies.
68
Overall in the derivation dataset we identified
121623 incident cases of cardiovascular disease
(including cardiovascular events before death and
death due to cardiovascular disease) and 148671
deaths from other causes, arising from a total of
16485396 person years of observation. Figure 1
shows the incidence of cardiovascular disease and
deaths from other causes by age and sex. The death
rates from other causes rise more steeply than
Table 1 |Baseline characteristics of the derivation and validation cohorts. Patients are free
from cardiovascular disease and not prescribed statins at baseline. Values are numbers
(percentages) of patients unless otherwise stated.
Derivation cohort
(n=2 343 759)
Validation cohort
(n=1 267 159)
Women 1 189 845 (50.8) 645 012 (50.9)
Mean (SD) age (years) 48.1 (14.3) 48.0 (14.2)
Mean (SD) Townsend score −0.2 (3.4) −0.3 (3.5)
Smoking status:
Non-smoker 1 176 386 (50.2) 631 545 (49.8)
Former smoker 356 697 (15.2) 193 974 (15.3)
Current smoker (amount not recorded) 99 100 (4.2) 59 178 (4.7)
Light smoker (<10 cigarettes/day) 142 369 (6.1) 71 037 (5.6)
Moderate smoker (10-19/day) 175 419 (7.5) 91 679 (7.2)
Heavy smoker (≥20/day) 136 202 (5.8) 74 056 (5.8)
Smoking status not recorded 257 586 (11.0) 145 690 (11.5)
Ethnic group:
White or not recorded 2 229 834 (95.1) 1 219 987 (96.3)
Indian 22 598 (1.0) 7 577 (0.6)
Pakistani 11 137 (0.5) 3 663 (0.3)
Bangladeshi 6 432 (0.3) 2 632 (0.2)
Other Asian 12 581 (0.5) 5 032 (0.4)
Caribbean 13 454 (0.6) 4 666 (0.4)
Black African 20 801 (0.8) 9 471 (0.8)
Chinese 5 915 (0.3) 3 068 (0.2)
Other 21 007 (0.9) 11 063 (0.8)
Clinical conditions:
Treated hypertension* 132 585 (5.7) 67 986 (5.4)
Type 2 diabetes 40 504 (1.7) 20 868 (1.7)
Family history of early coronary heart disease† 247 981 (10.6) 143 593 (11.3)
Atrial fibrillation 12 031 (0.5) 6 589 (0.5)
Chronic renal disease 3 594 (0.2) 1 917 (0.2)
Clinical values:
Systolic blood pressure recorded 2 027 470 (86.5) 1 081 944 (85.4)
Mean (SD) systolic blood pressure (mm Hg) 131.9 (20.5) 131.7 (20.5)
BMI recorded 1 773 567 (75.7) 949 434 (74.9)
Mean (SD) BMI (kg/m
2) 26.1 (4.5) 26.1 (4.5)
Smoking status and BMI recorded 1 754 250 (74.9) 937 808 (74.0)
Serum total and HDL cholesterol recorded 692 590 (29.6) 354 853 (28.0)
Mean (SD) total cholesterol:HDL cholesterol ratio 4.2 (1.3) 4.2 (1.3)
BMI=body mass index; HDL=high density lipoprotein.
*A recorded diagnosis of hypertension and treatment that could include angiotensin converting enzyme
inhibitors, angiotensin receptor blockers, aldosterone antagonists, β blockers, thiazides, or calcium channel
blockers.
†Heart disease in a first degree relative aged <60 years.
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women >70 years.
Adjusted hazard ratios for risk factors in the derivation
cohort
Table 2 shows the hazard ratios for men and women
for the cardiovascular lifetime risk model. The
adjusted hazard ratios for each predictor variable
were similar in size to those reported previously.
6
Smoking showed a dose-response relationship, with
thehighestriskofcardiovasculardiseaseamongheavy
smokers. Smoking status was more closely associated
with the risk of death from other causes than risk of
cardiovascular disease in both men and women, as
shown in fig 2.
Assessment of performance of the lifetime model in the
validation cohort
We determined the performance of the lifetime model
evaluated at 10 years. The ROC (receiver operating
characteristics) statisticin womenwas0.842 (95% con-
fidence interval 0.840 to 0.844) and in men was 0.828
(0.826 to 0.830). The R
2 statistic was 47.0% (46.5 to
47.5) in women and 43.4% (42.9 to 43.9) in men.
Table 3 shows the predicted and observed lifetime
risks and the ratio of predicted to observed risk, taking
account of death as a competing risk. The results show
a small degree of under-prediction in those at low pre-
dicted risk—for example, the ratio of predicted to
observed lifetime risk in the lowest 10th was 0.90 for
men and 0.82 for women. In the highest 10th of risk,
thepredicted:observedratiowas1.01formenand1.02
for women, suggesting good calibration in this group.
Distribution of lifetime and 10 year cardiovascular risk in
the validation cohort
Figure 3 shows the 50th centiles for lifetime risk of
cardiovascular disease and for QRISK2 10 year risk
at each age in men and women. The 50th centile for
lifetime risk remains fairly constant, increasing until
60 years in men and 65 years in women, after which
it begins to decline. In contrast, the 50th centile for
QRISK2 10 year risk increases steeply with age in
both men and women, crossing the 20% threshold for
risk at age 72 in women and age 65 in men. Across all
these patients, the 50th, 75th, 90th, and 95th centile
values for lifetime risk were 31%, 39%, 50%, and 57%
respectively.
Characteristic of patients in top 10% of lifetime risk and
10 year risk
Sincetherearenoacceptedthresholdsforlifetimerisk,
we decided to define a high lifetime risk as a value
above the 90th centile (that is, a lifetime risk of cardio-
vascular disease >50%) and for comparative purposes
defined a high 10 year risk as a QRISK2 score above
the 90th centile (that is, 10 year risk >23.4%). We used
these values to identify and compare the 10% of the
1267159 patients in the validation dataset with the
highest lifetime risk and the 10% with the highest
10 year risk.
Of the 10% classified at high risk with either the life-
time risk model (n=126716) or the 10 year risk model
(n=126715), only 18385 (14.5%) were high risk on
both measures. Table 4 shows the characteristics of
the patients with a high 10 year risk compared with
those with a high lifetime risk. Among those with a
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Fig 1 | Incidence of cardiovascular disease and deaths from
other causes per 1000 person years by age and sex in the
derivation cohort of 2343759 patients
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death from other causes by smoking status in men and
women in the derivation cohort of 2343759 patients
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with 69794 (55.1%) of those with a high 10 year risk.
Overall, the patients with the high lifetime risk were
morelikelytobeyounger,male,andmuchmorelikely
to have a positive family history of coronary heart dis-
ease than those with a high 10 year risk. There were
also more patients from South Asian ethnic groups
and current smokers in the high lifetime risk group.
Worked examples of individual lifetime cardiovascular risk
Clinical example 1
A54yearoldwhitewomanwhoisanon-smoker,from
anaffluentarea,andwithafamilyhistoryofpremature
coronary heart disease in a first degree relative, body
mass index of 33.2, systolic blood pressure of 150 mm
Hg; and a total cholesterol:HDL cholesterol ratio of
5.3, has a 10 year risk of cardiovascular disease of
14%, placing her below the current 10 year inter-
vention threshold of 20%. However, her lifetime risk
of cardiovascular disease is 62%, which places her
above the 95th centilefor lifetime risk (fig 4). A similar
person with better risk factors—that is, body mass
index 28, systolic blood pressure 128 mm Hg, total:
HDL cholesterol ratio 4—has a lifetime risk of 49%.
The age at which the cardiovascular disease risk
reaches 50% is the expected age for a cardiovascular
event to occur. In this example, with current risk fac-
tors, the expected age is 81 years (that is, in 27 years
time), but with better risk factor control this would be
delayed to around 95 years (14 years later).
Clinical example 2
A 31 year old Indian woman who is a non-smoker,
from a deprived area, and with a family history of pre-
maturecoronaryheartdiseaseinafirstdegreerelative,
bodymassindex27.2,systolicbloodpressure128mm
Hg, total cholesterol:HDL cholesterol ratio of 5, has a
10 year risk of 1% and a lifetime risk of 74%. With a
10 year risk of 1%, this woman falls below the 10 year
intervention threshold of 20%, but an intervention
might be recommended if a lifetime risk threshold of
50% was used instead (fig 5). A similar patient with a
total cholesterol:HDL cholesterol ratio of 4 has a life-
time risk of 69%.
With current risk factors, the expected age for a
cardiovascular event to occur is 80 years (in 49 years
time), but with better risk factor control this would be
around 83 years (three years later).
Clinical example 3
A 60 year old white man who is a heavy smoker with
diabetes, who has a total cholesterol:HDL cholesterol
Table 2 |Adjusted hazard ratios* for cardiovascular disease for individual predictor variables
in the derivation cohort of 2 343 759 patients
Variables
Adjusted hazard ratio (95% CI)
Women Men
Body mass index† 1.32 (1.22 to 1.44 ) 1.54 (1.45 to 1.63 )
Systolic blood pressure (per 20 mm Hg increase) 1.13 (1.12 to 1.14 ) 1.11 (1.10 to 1.12 )
Total cholesterol:HDL cholesterol ratio (per unit
increase)
1.17 (1.16 to 1.18 ) 1.18 (1.17 to 1.18 )
Townsend score (per 5 unit increase)‡ 1.13 (1.11 to 1.14 ) 1.06 (1.05 to 1.07 )
Smoking status:
Non-smoker 1.00 1.00
Former smoker 1.17 (1.14 to 1.21 ) 1.18 (1.16 to 1.21 )
Light smoker (<10 cigarettes/day) 1.39 (1.33 to 1.45 ) 1.38 (1.34 to 1.43 )
Moderate smoker (10-19/day) 1.57 (1.52 to 1.63 ) 1.55 (1.51 to 1.60 )
Heavy smoker (≥20/day) 1.84 (1.77 to 1.91 ) 1.79 (1.74 to 1.84 )
Ethnic group:
White or not recorded 1.00 1.00
Indian 1.42 (1.28 to 1.58 ) 1.50 (1.38 to 1.63 )
Pakistani 2.04 (1.78 to 2.34 ) 2.05 (1.84 to 2.28 )
Bangladeshi 1.61 (1.30 to 1.98 ) 2.14 (1.85 to 2.46 )
Other Asian 1.14 (0.92 to 1.4 0) 1.32 (1.12 to 1.56 )
Caribbean 1.03 (0.91 to 1.16 ) 0.71 (0.63 to 0.81 )
Black African 0.69 (0.54 to 0.89 ) 0.70 (0.56 to 0.86 )
Chinese 0.77 (0.55 to 1.08 ) 0.79 (0.58 to 1.06 )
Other 0.99 (0.85 to 1.16 ) 0.90 (0.78 to 1.04 )
Clinical conditions:
Family history of early coronary heart disease§ 1.67 (1.63 to 1.71 ) 1.84 (1.80 to 1.88 )
Type 2 diabetes 1.67 (1.60 to 1.73 ) 1.60 (1.55 to 1.66 )
Treated hypertension 1.33 (1.30 to 1.36 ) 1.37 (1.34 to 1.40 )
Rheumatoid arthritis 1.43 (1.35 to 1.53 ) 1.37 (1.26 to 1.50 )
Atrial fibrillation 1.89 (1.78 to 2.01 ) 1.63 (1.54 to 1.72 )
Chronic renal disease 1.67 (1.44 to 1.95 ) 1.59 (1.39 to 1.83 )
HDL=high density lipoprotein.
*Hazard ratios were adjusted for all other variables listed in the table.
†Fractional polynomial terms for body mass index: for women, (body mass index/10)
0.5; for men, ln(body mass
index/10).
‡Increasing Townsend scores indicate increasing levels of deprivation.
§Heart disease in a first degree relative aged <60 years.
Table 3 |Predicted and observed lifetime risk of
cardiovascular disease by 10th of predicted lifetime risk in
the validation cohort of 1 267 159 patients
Model decile
Mean lifetime risk (%) Ratio of predicted
to observed Predicted Observed
Women:
1 18.5 22.4 0.8
2 21.3 25.9 0.8
3 22.9 27.3 0.8
4 24.4 28.5 0.9
5 26.0 29.4 0.9
6 27.8 31.9 0.9
7 30.2 34.8 0.9
8 33.7 36.8 0.9
9 39.5 41.3 1.0
10 51.9 50.8 1.0
Men:
1 22.5 25.0 0.9
2 27.2 32.1 0.9
3 29.8 34.9 0.9
4 32.0 37.3 0.9
5 34.2 39.3 0.9
6 36.6 42.1 0.9
7 39.5 44.9 0.9
8 43.5 47.5 0.9
9 49.9 51.0 1.0
10 64.4 63.7 1.0
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body mass index of 27.5 would have a 10 year risk of
24% and a lifetime risk of 41%. A similar patient who
was a non-smoker would have a 10 year risk score of
16% and a lifetime risk of 44%.
These values might seem counterintuitive in that,
while we would expect the 10 year risk estimate to be
lower for a non-smoker than a heavy smoker, we
would not expect the lifetime risk to increase for the
non-smoker. However, a non-smoker has a lower risk
of dyingfrom othercauses (suchas lungcancer)than a
heavy smoker, and this increases his or her chances of
living longer and thus increases the lifetime risk of
developing cardiovascular disease.
DISCUSSION
Summary of main findings
We have developed, validated, and evaluated a new
QRISK model to estimate lifetime risk of cardio-
vascular disease using routinely collected data from
electronic health records. Compared with using a
10 year QRISK2 score, a lifetime approach will lead
to patients being identified for intervention at a
younger age, with a higher proportion of men, more
people from non-white ethnic groups, and more with
a family history of premature coronary heart disease.
Comparison with other studies
Although other studies have reported methods to esti-
mate 30 year or lifetime risk,
1011 ours is the first to esti-
mate lifetime risk of cardiovascular disease based on
contemporaneous UK data from primary care. We
think ours is also the first study to include a wider
range of risk factors such as ethnicity, social depriva-
tion, rheumatoid arthritis, chronic renal disease, atrial
fibrillation, and family history of premature coronary
heart disease.
6
The Framingham investigators found that 10 year
riskswerebettershorttermpredictorsofcardiovascular
disease incidence than a lifetime equation but underes-
timatedlongtermrisk,particularlyinyoungerpeople.
22
A recent Framingham study by Lloyd-Jones et al esti-
matedlifetimerisksat50yearsofageandreportedrisks
of 52% for men and 39% for women.
11 These are con-
siderablyhigherthanthe50thcentileforlifetimeriskin
ourstudyforpatientsaged50years,whichwas38% for
men and 29% for women. The higher average risks
derived from the Framingham cohort reflect the
known tendency of algorithms based on older US data
to over-predict risk in contemporary European
settings.
23 The reasons for this may include a broader
definition of outcomes
1122 and falling disease incidence
since the peak of the epidemic in the 1970s.
1122
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the cumulative cardiovascular risk. 
For the woman’s lifetime risk with better risk factor control, select the 
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Fig 4 | A 54 year old woman’s individual risk of cardiovascular
disease over remaining lifetime—current risk versus risk with
better risk factor control (see text for details).
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Fig 5 | A 31 year old woman’s individual risk of cardiovascular
disease over remaining lifetime—current risk versus risk with
better risk factor control (see text for details)
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ofestimatinglifetimeriskofcardiovasculardiseaseand
have developed an alternative approach to communi-
cating short term absolute risk that incorporates the
benefits of relative risk and long term risk measures.
24
This approach may be more intuitive for patients and
clinicians,but thereare concerns that most individuals
havehighlifetimerisksandthatthiswouldleadtosimilar
managementforeveryone.
24Ourstudy,however,sug-
gests that it is possible to define centile values which
could be used as thresholds for classifying additional
high risk patients, although our values are clearly
applicable only to patients from a UK setting.
Strengths of study
Ourlifetimemodelisbasedentirelyonclinicallyavail-
able data recorded in NHS electronic healthcare
recordsas partofroutine clinicalcare. Theadvantages
of using the QResearch database include the potential
forcontinuedupdating.
2526Thus,ourmodelisderived
from a large, ethnically diverse, contemporaneous
population which is representative of those patients
with whom the risk estimation method is likely to be
used.Themodelcanalsobeupdatedtotakeaccountof
improvementsindataquality(suchasincreasingnum-
bers of patients with ethnicity or smoking status
recorded)orrefinedovertimetoreflecttrendsinpopu-
lation characteristics, changes in clinical requirements
such as a need to estimate cardiovascular risk over a
broader age range,
27 or to accommodate improved
methods for communicating cardiovascular risk to
patients.
9
Our lifetime model estimates risks for non-smokers,
former smokers, and light, moderate, and heavy smo-
kersratherthansimplyforcurrentsmokersversuscur-
rent non-smokers as in the 10 year QRISK2
algorithm.
6 As others have reported, the risks asso-
ciated with deaths from other causes were also
marked.
11 There is a differential effect of smoking sta-
tus on cardiovascular risk and risk of death from other
causes, with a stronger effect on the risk of death from
other causes. This probably explains the observation
that, when competing risks are being accounted for,
there may be cases when the lifetime risks of cardio-
vascular disease in smokers are lower than those for
similar patients who are non-smokers (such as with
Table 4 |Characteristics of the 10% of patients in the validation cohort who were at highest risk of cardiovascular disease
based on QRISK2 10 year risk score (≥23.4%) and on lifetime risk (≥50%). Values are numbers (percentages) of patients
unless otherwise stated
10 year risk Lifetime risk
Men (n=69 794) Women (n=56 921) Men (n=93 426) Women (n=33 290)
Mean (SD) age (years) 71.7 (7.6) 76.7 (6.0) 45.2 (10.6) 50.1 (11.7)
Mean (SD) Townsend score −0.1 (3.5) 0.3(3.5) −0.5 (3.4) 0.5 (3.5)
Current smoker 20 300 (29.1) 11 845 (20.8) 30 466 (32.6) 10 639 (32.0)
Age band (years):
30–44 178 (0.3) 76 (0.1) 49 009 (52.5) 11 593 (34.8)
45–64 11 523 (16.5) 2 376 (4.2) 39 570 (42.4) 17 490 (52.5)
65–74 30 753 (44.1) 13 728 (24.1) 4 469 (4.8) 3 725 (11.2)
75–84 27 340 (39.2) 40 741 (71.6) 378 (0.4) 482 (1.4)
Ethnic group:
White or not recorded 68 652 (98.4) 56 326 (99.0) 83 411 (89.3) 29 054 (87.3)
Indian 325 (0.5) 149 (0.3) 2 872 (3.1) 1 135 (3.4)
Pakistani 236 (0.3) 153 (0.3) 1 870 (2.0) 1 162 (3.5)
Bangladeshi 209 (0.3) 67 (0.1) 1 504 (1.6) 568 (1.7)
Other Asian 110 (0.2) 38 (0.1) 1 784 (1.9) 342 (1.0)
Caribbean 90 (0.1) 89 (0.2) 171 (0.2) 344 (1.0)
Black African 26 (0.0) 8 (0.0) 170 (0.2) 39 (0.1)
Chinese 16 (0.0) 10 (0.0) 142 (0.2) 30 (0.1)
Other 130 (0.2) 81 (0.1) 1 502 (1.6) 616 (1.9)
Clinical conditions:
Treated hypertension 14 196 (20.3) 14 833 (26.1) 10 066 (10.8) 7 865 (23.6)
Type 2 diabetes 6 907 (9.9) 5 369 (9.4) 3 425 (3.7) 1 784 (5.4)
Family history of early coronary heart disease* 9 037 (12.9) 6 005 (10.5) 53 600 (57.4) 27 601 (82.9)
Atrial fibrillation 2 712 (3.9) 2 327 (4.1) 792 (0.8) 381 (1.1)
Chronic renal disease 417 (0.6) 270 (0.5) 155 (0.2) 91 (0.3)
Clinical values
Mean (SD) BMI (kg/m
2) 26.8 (20.8) 26.5 (4.7) 28.5 (4.5) 29.4 (5.4)
Mean (SD) total:HDL cholesterol ratio 4.7 (1.5) 4.4 (1.4) 5.6 (1.6) 5.1 (1.4)
Mean (SD) systolic blood pressure (mm Hg) 150 (21) 154 (22) 138 (20) 144 (22)
BMI=body mass index. HDL=high density lipoprotein
*Heart disease in a first degree relative aged <60 years.
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because the non-smokers have a reduced risk of
deathfromothercausesandsoarelikelytolivelonger,
whichincreasesthelengthoftimeoverwhichtheymay
developcardiovasculardisease.Our resultshavegood
facevalidity,andthefinergradingofsmokingcannow
be incorporated into the QRISK2 10 year risk
algorithm.
6
Our lifetime model is flexible and can be used to
calculate risk over different age ranges: for example,
it could be used to estimate risk up to the age of 75
rather than 95, since cardiovascular events before age
75 could be considered as premature events.
Lastly, an important advantage of our approach is
that the calculation incorporates estimates of the prob-
ability that a patient will be alive and free from cardio-
vascular disease for any age up to 95, accounting for
individual risk factors rather than applyingpopulation
values of life expectancy as in some other studies.
18
Limitations of study
Aswithallobservationalstudies,ourstudyissubjectto
bias and confounding, including the effects of missing
data. These limitations and the analyses to minimise
their effect have been discussed in detail in previous
papers.
6-828-32 Although we have presented a model
for lifetime risk, this has been derived from a contem-
poraneous UK population with data collected and
recorded over a follow-up period of up to 16 years.
While this may be a limitation, data collection over a
longer follow-up period could also be problematic
giventemporal changesin incidenceof cardiovascular
disease and associated risk factors.
11 There have also
been temporal changes in use of statins, although
these changes have been most marked in the last few
years of our study period and previous sensitivity ana-
lyses suggest that our models remain robust.
33 Our
approach, however, uses age as the underlying time
function and has enabled us to derive lifetime risk of
cardiovasculardiseaseuntiltheageof95.Themodelis
based on contemporaneous data and minimises the
potential impact of bias due to temporal changes in
populations, risk factors, and interventions. Neverthe-
less, the models do not account for secular trends
across the age range.
Although our validation has been undertaken in a
separate set of patients and practices from the ones
used to develop the models, they all use the same clin-
icalcomputersystem(EgtonMedicalInformationSys-
tems, EMIS). This potentially gives our algorithm
some homeadvantage, though other studieshave vali-
dated QRISK on practices using a different clinical
computer system and have found strikingly similar
results.
73435In addition, EMIS is used in 59% of prac-
tices in England and provides the clinical records for
over 39 million patients nationally.
Lifetime risk for assessment at individual level
The QRISK lifetime model could be used at the indi-
vidual level to communicate cardiovascular risk to
patients, especially younger patients with family
historiesofcardiovasculardisease,forwhomearlylife-
style changes or pharmacological intervention could
lead to significant gains over their lifetime.
9 A web
based calculator (www.qrisk.org/lifetime) could be
used to display to both patient and clinician, the cur-
rent risk trajectory alongside the risk for the same
patient with better control of modifiable risk factors
suchassmoking,bodymassindex,systolicbloodpres-
sure, and total cholesterol:HDL cholesterol ratio.
Althoughourstudydidnotassessthepotentialbenefits
of interventions, our first clinical examples suggest
marked differences in lifetime risk for patients with
goodcontrolofriskfactors,especiallythoseatyounger
ages, compared with those with more adverse profiles.
Thisisconsistentwithotherstudies,whichhaveshown
that individuals with a high 30 year risk may not be
identified using a 10 year risk prediction.
101136
While there is good evidence for lifestyle modifica-
tion at all ages,
3738 it is not clear whether individual
treatment decisions should be based on lifetime risk
instead of 10 year risk (see worked clinical examples
above).Ifinterventionswerefocusedonpatientsabove
the 90th centile of lifetime risk, then a person at high
lifetime risk might receive treatment at an early age
(such as the 31 year old woman in clinical example 2)
even though cumulative absolute risk would remain
well below 20% for the next 30 years (see fig 3). In
other words, younger people would tend to have long
term treatment with few short term gains, and, as fig 3
shows, most lifetime risk accrues after the age of
65 years. In primary prevention of cardiovascular dis-
ease in people at lower levels of absolute risk, there is
currentlyalackoftrialevidenceshowingbenefitsfrom
statintreatmentintermsoftotalmortality.
39Theexpo-
sure of large numbers of people at low risk to potential
harm
282940 over a prolonged period in the absence of
suchevidence isa majorissue.However,theremay be
more benefits from lifestyle change at a younger age
without the potential harms. Similarly, it is far from
certain whether the most elderly people (those over
the age of 90) with a high lifetime risk would be a
patient group that clinicians would wish to treat.
Future research
Our study leaves many unanswered questions, includ-
ing whether early intervention in people with a high
lifetime risk but low 10 year risk would have a greater
clinicalbenefitthanlaterintervention;whetherpeople
at low absolute risk would value long term treatments
withlittleshorttermgain;determiningtheappropriate
thresholdforlifetime risktobalancetheexpectedben-
efits (such as event-free years) against the potential
adverse effects of interventions such as statins
282940;
and determining the most appropriate and effective
methods for communicating absolute and relative
risk to patients.
Conclusion
We have developed and validated a new model for
estimating lifetime risk of cardiovascular disease. This
approach identifies different people being at high risk
RESEARCH
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with the 10 year QRISK2 score, the lifetime approach
identified patients for intervention at a younger age,
with a higher proportion of men, more people from
ethnicminoritygroups,andmorewithafamilyhistory
of premature coronary heart disease. Although life-
style interventions at an earlier age could be advanta-
geous,medicalinterventionscarryrisksassoonasthey
areinitiated,sothenetpotentialbenefitremainsuncer-
tain. Additional research is needed to closely examine
the cost effectiveness and acceptability of such an
approach.
Thelifetimeriskcalculatorisavailableatwww.qrisk.org/lifetime/(freefor
non-commercial research, educational, and personal use).
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